MSM’s weekly comment:
“Among the week’s other losers, Faron Pharma suffered a brutal 60 per cent drop after unveiling plans to raise €40 million.
The reaction appears disproportionate given the drug developer intends to use the new investment to advance its blood cancer treatment bexmarilimab into later-stage clinical trials, a necessary step that could deliver long-term returns.”
In my opinion, a fairly sensible comment from the big world to the big world.